Innate Pharma Beheer

Beheer criteriumcontroles 3/4

De CEO Innate Pharma is Mondher Mahjoubi, benoemd in Dec2016, heeft een ambtstermijn van 6.75 jaar. De totale jaarlijkse vergoeding van { bedraagt € 1.09M, bestaande uit 43.1% salaris en 56.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.64% van de aandelen van het bedrijf, ter waarde € 1.35M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.2 jaar en 4.8 jaar.

Belangrijke informatie

Mondher Mahjoubi

Algemeen directeur

€1.1m

Totale compensatie

Percentage CEO-salaris	43.1%
Dienstverband CEO	6.8yrs
Eigendom CEO	0.6%
Management gemiddelde ambtstermijn	5.2yrs
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Mondher Mahjoubi's beloning veranderd ten opzichte van Innate Pharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2023	n/a	n/a	-€63m
Mar 31 2023	n/a	n/a	-€60m
Dec 31 2022	€1m	€470k	-€58m
Sep 30 2022	n/a	n/a	-€40m
Jun 30 2022	n/a	n/a	-€22m
Mar 31 2022	n/a	n/a	-€34m
Dec 31 2021	€1m	€470k	-€45m
Jun 30 2021	n/a	n/a	-€8m
Mar 31 2021	n/a	n/a	-€4m
Dec 31 2020	€1m	€470k	-€829k
Sep 30 2020	n/a	n/a	-€54m
Jun 30 2020	n/a	n/a	-€44m
Mar 31 2020	n/a	n/a	-€33m
Dec 31 2019	€1m	€470k	€8m
Sep 30 2019	n/a	n/a	€5m
Jun 30 2019	n/a	n/a	€31m
Mar 31 2019	n/a	n/a	€17m
Dec 31 2018	€1m	€470k	€3m
Sep 30 2018	n/a	n/a	-€19m
Jun 30 2018	n/a	n/a	-€40m
Mar 31 2018	n/a	n/a	-€44m
Dec 31 2017	€750k	€470k	-€48m
Sep 30 2017	n/a	n/a	-€28m
Jun 30 2017	n/a	n/a	-€8m
Mar 31 2017	n/a	n/a	€3m
Dec 31 2016	€2k	n/a	€13m

Compensatie versus markt: De totale vergoeding ($USD 1.17M ) Mondher } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 787.21K ).

Compensatie versus inkomsten: De vergoeding van Mondher is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Mondher Mahjoubi (65 yo)

6.8yrs

Tenure

€1,091,442

Compensatie

Dr. Mondher Mahjoubi, M.D., serves as Chairman at PDC line Pharma SAS since June 2020. He has been the Chairman of Executive Board and Chief Executive Officer of Innate Pharma S.A. since December 30, 2016....

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Herve Brailly	Co-Founder & Chairman of Supervisory Board	24.7yrs	€100.00k	0.92% € 1.9m
Mondher Mahjoubi	Chairman of Executive Board & CEO	6.8yrs	€1.09m	0.64% € 1.4m
Yannis Morel	Executive VP of Product Portfolio Strategy & Business Development and Member of Executive Board	8.3yrs	€511.78k	0.19% € 407.1k
François Romagné	Founder	no data	geen gegevens	geen gegevens
Eric Vivier	Founder	5.7yrs	geen gegevens	0.23% € 485.7k
Marc Bonneville	Founder	no data	geen gegevens	geen gegevens
Jean Fournié	Founder	no data	geen gegevens	geen gegevens
Alessandro Moretta	Founder	no data	geen gegevens	geen gegevens
Frederic Lombard	Senior VP & CFO	2.4yrs	geen gegevens	0.0012% € 2.5k
Odile Belzunce	Vice President of Compliance & Operations	4.7yrs	geen gegevens	0.050% € 106.1k
Henry Wheeler	Vice President of Investor Relations & Communication	less than a year	geen gegevens	0.0012% € 2.5k
Claire de Blanquat	VP of Legal & Corporate Affairs and Secretary of the Supervisory Board	less than a year	geen gegevens	0.0012% € 2.5k

5.2yrs

Gemiddelde duur

54.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van IDDA is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Herve Brailly	Co-Founder & Chairman of Supervisory Board	6.8yrs	€100.00k	0.92% € 1.9m
Olivier Martinez	Member of Supervisory Board	no data	geen gegevens	geen gegevens
Ruslan Medzhitov	Strategic Advisory Board Member	4.8yrs	geen gegevens	geen gegevens
Gilles Brisson	Independent Member of Supervisory Board	16.2yrs	€30.00k	0.091% € 192.1k
Jean-Yves Blay	Independent Member of Supervisory Board	5.8yrs	€20.00k	0.000060% € 127.0
Irina Staatz-Granzer	Independent Vice Chairman of Supervisory Board	14.3yrs	€41.00k	0.031% € 66.0k
Pascale Boissel	Independent Member of Supervisory Board	3.3yrs	€53.67k	0.0012% € 2.6k
Miriam Merad	Chairman of Strategic Advisory Board	4.8yrs	geen gegevens	geen gegevens
Veronique Chabernaud	Independent Member of Supervisory Board	8.4yrs	€51.00k	0.000010% € 21.2
Sebastian Amigorena	Strategic Advisory Board Member	4.8yrs	geen gegevens	geen gegevens
Aurelien Marabelle	Strategic Advisory Board Member	4.8yrs	geen gegevens	geen gegevens
Tanguy Seiwert	Strategic Advisory Board Member	4.8yrs	geen gegevens	geen gegevens

4.8yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IDDA wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Innate Pharma Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Innate Pharma S.A., Annual General Meeting, May 22, 2025

Innate Pharma SA Announces Board Changes

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma S.A. Announces Executive Changes

Innate Pharma S.A. Announces Executive Changes

Recent updates

Innate Pharma S.A., Annual General Meeting, May 22, 2025

Innate Pharma S.A. to Report First Half, 2025 Results on Sep 17, 2025

Innate Pharma SA Announces Board Changes

Araris Biotech AG entered into an agreement to acquire ADC Transglutaminase Conjugation Technology Patents Portfolio from Innate Pharma S.A. (ENXTPA:IPH).

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis Fungoides

Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin’s Lymphoma

Innate Pharma S.A. has filed a Follow-on Equity Offering in the amount of $75 million.

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

Innate Pharma S.A. Announces New Clinical Data for Lacutamab and SAR443579/ IPH6101 at ASH 2023

Innate Pharma S.A. to Report Q2, 2024 Results on Sep 12, 2024

Innate Pharma S.A. Provides Update on Lacutamab Clinical Program

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

Innate Pharma S.A. Announces Executive Changes

Innate Pharma S.A. Announces Executive Changes

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma S.A. Announces First Patient Dosed in Matisse Trial of IPH5201 in Early Stage Lung Cancer

Innate Pharma Sa Highlights Increased Lacutamab Clinical Activity from Interim Results of Phase 2 Tellomak Study with Updated Olsen Criteria

Innate Pharma S.A. Highlights Proprietary Tetra-Specific Anket Nk Cell Engager Iph6501 At the Eha 2023 Congress

Innate Pharma S.A. Announces SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd